New Trial Results: Kiora's KIO-301 Demonstrates Meaningful Vision Improvements in Retinitis Pigmentosa

Analyst Info

H.C. Wainwright & Co. Yi Chen
Alliance Global Partners Ben Haynor
Zacks SCR Elizabeth Senko
Maxim Group Jason McCarthy

Kiora Pharmaceuticals is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Kiora Pharmaceuticals’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kiora Pharmaceuticals or its management. Kiora Pharmaceuticals does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Loading RSS Feed